Who is sponsoring NCT01856361?

NCT01856361 is sponsored by Weill Medical College of Cornell University.

What condition does NCT01856361 study?

NCT01856361 studies Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility.

What drugs are being tested in NCT01856361?

Interventions: Ramipril, Placebo.

What is the status of NCT01856361?

NCT01856361 is currently TERMINATED.

Last reviewed 2017-04-27 · How we verify

Ramipril for the Treatment of Oligospermia: A Double-Blind Randomized Control Trial

NCT01856361 NA TERMINATED Results posted

This is a randomized controlled trial to evaluate the effect of ramipril in stimulating and promoting sperm production in men with low sperm count. Ramipril is an Angiotensin Converting Enzyme Inhibitor (ACEI) currently used to treat high blood pressure. However, previous studies have shown that this class of medications can improve sperm parameters. The purpose of this study is to evaluate the efficacy of ramipril compared to placebo (Substance That is not known to have treatment effect), in improving sperm density in infertile men with documented low sperm count. This study will help us identify subjects that might benefit from treatment with this medication, and the effect it will have on sperm count, shape, and motility.

Details

Lead sponsor	Weill Medical College of Cornell University
Phase	NA
Status	TERMINATED
Enrolment	2
Start date	2013-07
Completion	2016-06

Conditions

Oligospermia
Teratospermia
Asthenozoospermia
Male Infertility

Interventions

Ramipril
Placebo

Primary outcomes

Sperm Density in Infertile Men With Documented Oligospermia. — 32 weeks

Countries

United States